Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TAGGED: A Phase 2 Study Using Low Dose/Metronomic Trabectedin, Gemcitabine, and Dacarbazine as 2nd/3rd/4th Line Therapy for Advanced Soft Tissue Sarcoma

NCT04535271 is registered in ClinicalTrials.gov with Sarcoma Oncology Research Center, LLC as lead sponsor.

NCT NCT04535271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04535271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TAGGED: A Phase 2 Study Using Low Dose/Metronomic Trabectedin, Gemcitabine, and Dacarbazine as 2nd/3rd/4th Line Therapy for Advanced Soft Tissue Sarcoma
Lead sponsor
Sarcoma Oncology Research Center, LLC
Phase
Phase 2
Overall status
Recruiting
Start date
September 9, 2021
Completion date
March 30, 2029
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leiomyosarcoma